CLINICAL USE

H2-receptor antagonist

DOSE IN NORMAL RENAL FUNCTION

Oral: 150–600 mg dailyIV: 300–480 mg daily

PHARMACOKINETICS

  • Molecular weight                           :331.5
  • %Protein binding                           :35
  • %Excreted unchanged in urine     : 60
  • Volume of distribution (L/kg)       :0.8–1.3
  • half-life – normal/ESRD (hrs)      :1–2/3.5–11

    DOSE IN RENAL IMPAIRMENT

    GFR (mL/MIN)

  • 20 to 50     : 150–300 mg daily <20 150 mg daily

    DOSE IN PATIENTS UNDERGOING RENAL REPLACEMENT THERAPIES

  • CAPD                :Not dialysed. Dose as in GFR<20 mL/min
  • HD                     :Not dialysed. Dose as in GFR<20 mL/min
  • HDF/high flux   :Unknown dialysability. Dose as in GFR<20 mL/min
  • CAV/VVHD      :Unknown dialysability. Dose as in GFR<20 mL/min

    IMPORTANT DRUG INTERACTIONS

    Potentially hazardous interactions with other drugs

  • Antifungals: absorption of itraconazole and ketoconazole reduced

    ADMINISTRATION

    Reconstition

    –

    Route

    Oral, IV

    Rate of Administration

    Continuous

    IV infusion

    : Dilute 300 mg in 150 mL. Rate 10 mg/hour. Bolus: Dilute 100 mg in 50 mL and give over 15 minutes

    Comments

    Compatible with sodium chloride 0.9% or glucose 5%.To maintain gastric pH ≥4, a continuous infusion of 10 mg/hour is recommended

    OTHER INFORMATION

    The effect of haemodialysis is unproven. It is not expected to be efficient since nizatidine has a large volume of distribution.

    • Tags:

    Related News

    ffddfd

    Hyperlipidemia